Pharmacy Tirzepatide

Tirzepatide vs Semaglutide: Head-to-Head Research — Pharmacy Tirzepatide

The short version

Tirzepatide vs semaglutide has been tested directly in two large clinical trials — SURPASS-2 (type 2 diabetes) and SURMOUNT-5 (obesity without diabetes) — and in a large retrospective cohort study. In every comparison, tirzepatide produced larger reductions in blood sugar and body weight. The difference is statistically significant and clinically meaningful in both head-to-head trials. The mechanism is the dual GIP+GLP-1 receptor activation — engaging two incretin pathways instead of one appears to produce better effects than semaglutide's single-receptor approach. The figures are below.

Tirzepatide vs semaglutide: SURPASS-2 (HbA1c and weight in type 2 diabetes)

SURPASS-2 was an open-label 40-week phase 3 randomised controlled trial in 1,879 adults with type 2 diabetes, comparing once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) against once-weekly subcutaneous semaglutide 1 mg [3].

HbA1c reductions (percentage points from baseline):

  • Tirzepatide 5 mg: −2.01
  • Tirzepatide 10 mg: −2.24
  • Tirzepatide 15 mg: −2.30
  • Semaglutide 1 mg: −1.86

All three tirzepatide doses were noninferior and statistically superior to semaglutide. The advantage ranged from 0.15 to 0.44 percentage points [3].

Body-weight reductions (kg):

  • Tirzepatide 5 mg: −7.8 kg
  • Tirzepatide 10 mg: −10.3 kg
  • Tirzepatide 15 mg: −12.4 kg
  • Semaglutide 1 mg: −6.2 kg

Treatment differences of −1.9, −3.6, and −5.5 kg at the three tirzepatide doses [3].

In a 2026 post-hoc analysis of SURPASS-2 (Neves JS, et al., Diabetologia), standard composite therapeutic targets (HbA1c <7%, BP <140/90 mmHg, LDL <1.8 mmol/L, >10% weight loss, ≥3 goals met) were achieved by 42%, 53%, and 57% of tirzepatide participants (5, 10, 15 mg) versus 34% with semaglutide. Intensive targets were met by 15%, 20%, and 29% versus 8% [12].

Tirzepatide results in SURMOUNT-5: head-to-head in obesity

SURMOUNT-5 was a phase 3b open-label randomised controlled trial in 751 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related condition) without type 2 diabetes. Participants were randomised to each drug's maximum tolerated dose — tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg — for 72 weeks [5].

Body-weight change at 72 weeks:

  • Tirzepatide: −20.2%
  • Semaglutide: −13.7%
  • Difference: approximately 6.5 percentage points (P<0.001)

Tirzepatide also produced a greater reduction in waist circumference and higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss thresholds [5].

Quality-of-life readouts from SURMOUNT-5 (Shukla AP, et al., Diabetes Obes Metab, 2026) found greater health-related quality-of-life benefit with tirzepatide versus semaglutide, concentrated in physical-function-related domains. The General Health domain improved more with tirzepatide (5.45 vs 4.20, p=0.003), and participants with limited baseline physical function showed greater improvement in Physical Component Summary scores with tirzepatide [37].

Real-world tirzepatide results: the TriNetX retrospective cohort

A propensity-matched retrospective cohort study using the TriNetX international database (Anson M, et al., EClinicalMedicine, 2024) compared tirzepatide versus semaglutide in real-world clinical practice [8].

Without pre-existing type 2 diabetes (n=13,846):

  • New-onset type 2 diabetes: HR 0.73 (95% CI 0.58–0.92, p<0.001) — a 27% lower risk with tirzepatide
  • Weight loss: −7.7 kg with tirzepatide versus −4.8 kg with semaglutide

With pre-existing type 2 diabetes (n=8,446):

  • Composite cardiovascular outcome (all-cause mortality, cerebral infarction, acute coronary syndrome, heart failure): HR 0.54 (95% CI 0.38–0.76)
  • Cerebral infarction specifically: HR 0.45
  • All-cause mortality: HR 0.33

As a retrospective observational study, this cohort is subject to confounding not fully addressed by propensity matching. The direction and magnitude of the results are consistent with the randomised trial programme, and the study's scale — tens of thousands of patients — extends the evidence to real-world clinical populations [8].

Meta-analytic and indirect evidence

A 2025 systematic review and meta-analysis of 16 studies (5,997 patients) found tirzepatide had a statistically significant HbA1c advantage over semaglutide: mean difference −0.45 percentage points (95% CI −0.88 to −0.02, p=0.04). No clear superiority was observed between the two agents for weight or fasting blood sugar change in this analysis, which pooled different doses across heterogeneous trial designs [9].

An indirect treatment comparison via a common placebo arm (Ciudin A, et al., Diabetes Obes Metab, 2025) examined tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in adults with obesity and type 2 diabetes (using SURMOUNT-2 and STEP 2 data). Tirzepatide 10 and 15 mg showed significantly greater weight, BMI, and HbA1c reductions. Tirzepatide 15 mg showed significantly greater odds of ≥5% and ≥15% weight reduction and greater improvements in waist circumference, fasting plasma glucose, and triglycerides [36].

For the full Tirzepatide research record across all trial programmes, see the research page. The tirzepatide weight loss page covers the SURMOUNT-specific weight data in greater detail.